期刊文献+

盐酸度洛西汀肠溶胶囊体外溶出介质筛选及验证 被引量:1

Screening and Verification of Dissolution Medium for Duloxetine Hydrochloride Enteric Capsules in Vitro
下载PDF
导出
摘要 建立了盐酸度洛西汀肠溶胶囊的溶出测定方法,并筛选出能够指导体内外相关性的溶出曲线,用于仿制药的一致性评价,为体内外相关性提供数据支持。采用Aglient ZORBAX SB-C8柱(75 mm×4.6 mm×3.5μm),流动相为磷酸盐缓冲液-甲醇-四氢呋喃(体积比为587∶323∶90),流速为1.0 ml/min,检测波长为230nm,柱温为45℃。在0.006~0.075 mg/m L范围内,盐酸度洛西汀质量浓度与峰面积呈线性关系,回收率在99.5%~102.2%之间。参照《仿制药生物等效性指导原则》筛选出4种介质用于注册批样品稳定性检测,其液相色谱检测方法具有准确和快速等特点。 A dissolution determination method for duloxetine hydrochloride enteric-coated capsules was established,and the dissolution curve which can guide the correlation between in vivo and in vitro was selected, so as to evaluate the consistency of generic drugs and provide data support for the correlation between in vivo and in vitro. Aglient ZORBAX SB-C8(75 mm×4.6 mm×3.5 μm) was used, the mobile phase was phosphate buffer-methanol-tetrahydrofuran(the volume ratio was 587∶323∶90), the flow rate was 1.0 mL/min, the detection wavelength was 230 nm, and the column temperature was 45 ℃. The linear range of the method was 0.006-0.075 mg/mL, and the recovery rate was 99.5%-102.2%. Four kinds of media were screened out according to the Guiding Principles of Bioequivalence of Generic Drugs for the stability test of registered batches, and the liquid chromatography detection method was accurate and rapid.
作者 程凌飞 姚振江 余昌仲 Manisha 吴兰 王蓉 CHENG Lingfei;YAO Zhenjiang;YU Changzhong;Manisha;WU Lan;WANG Rong
出处 《上海化工》 CAS 2022年第6期58-61,共4页 Shanghai Chemical Industry
关键词 高效液相色谱法 盐酸度洛西汀 溶出曲线 HPLC Duloxetine hydrochloride Dissolution curve
  • 相关文献

参考文献3

二级参考文献28

  • 1Li ZS, Jinan L, Yang Z. Comparative effectiveness in pain-related out-comes and health care utilizations between veterans with major depressivedisorder treated with duloxetine and other antidepressants : A retrospec-tive propensity score-matched comparison [ J] . Pain Practi,2012,12:374-384. 被引量:1
  • 2Lai CH,Wu YT. Frontal regional homogeneity increased and temporal re-gional homogeneity decreased after remission of first-episode drug-na. vemajor depressive disorder with panic disorder patients under duloxetinetherapy for 6 weeks[ J] - J Affect Disord,2012,136:453 -458. 被引量:1
  • 3Oakes TM, Myers AL, Marangell LB, et al. Assessment of depressivesymptoms and functional outcomes in patients with major depressive dis-order treated with duloxetine versus placebo : primary outcomes from twotrials conducted under the same protocol[ J]. Human Psychopharmacol,2012,27:47-56. 被引量:1
  • 4Ulu S^Elmali F. Validated spectrophotometric method for the deteimina-tion,spectroscopic characterization and thermal stmctural {malysis of du-loxetine with 1, 2-naphthoquinone-4-sulphonate [ J]. Optics Spectr,2012,112:431 -437. 被引量:1
  • 5Reddy P,Sreeramulu J,Naidu P,et al. Stability Indicating Fast LC forthe Simultaneous Estimation of Intermediates and Degradants (rf Duloxe-tine Hydrochloride[ J]. Chromatographia ,2010,71:95 - 100. 被引量:1
  • 6Zhao RK,Cheng G,Tang J,et al. Pharmacokinetics of duloxetine hydro-chloride enteric-coated tablets in healthy Chinese volunte.B : A random-ized ,open-label, single-and multiple . dose study [ J]. Clin Therapeu-tics ,2009,31 :1022 -1036. 被引量:1
  • 7Musenga A,Amore M, Mandrioli H. Determination of duloxetine in hu-man plasma by capillary ^ectrophoresis with laser-induced fluorescencedetection[ J]. J Chromatc^r B Analyt Technol Biomed life Sci,2009,877:1126-1132. 被引量:1
  • 8国家食品药品监督管理局.化学药物稳定性研究技术指导原则[S].2005.3. 被引量:3
  • 9Detke M J, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression [ J]. Journal of Psychiatric Research, 2002,36: 383-390. 被引量:1
  • 10Detke MJ,Lu Y, Goldstein DJ, et al. Duloxetine, 60rag daily, for major depressive disorder: a randomized double-blind placebo con- trolled trim [J]. J Clin Psychiatry, 2002, 63(4) : 308-315. 被引量:1

共引文献9

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部